ESMO WCGIC 2022 | Targeted therapies for patients with HER2+ colorectal cancer
Jonathan Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the key points from his talk at ESMO WCGIC 2022 on targeted therapies for patients with HER2+ colorectal cancer, including discussions of the HERACLES (NCT03225937) and MOUNTAINEER (NCT03043313) trials. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
Disclosures
Consultant or advisory role: Abbvie, Takeda, AstraZeneca, Bayer, GSK, Inivata, Mereo Biopharma, Natera, Pfizer, Pionyr Immunotherapeutics, Seagen, Silverback Therapeutics, Viatris, Zentalis Compensated: Yes
Research funding or contracted research: Amgen, Bayer, Erasca, Seagen, Daiichi-Sankyo, Gossamer Bio, AStar D3, Sanofi, Roche/ Genentech, Curegenix, Nektar, Abbvie, Silverback Therapeutics Compensated: No
